Rev. OFIL 2017, 27;2:154-158
Fecha de recepción: 15/03/2016 – Fecha de aceptación: 21/11/2016
Escudero Vilaplana B, Santiago Prieto E, Manso Manrique M, Sánchez Guerrero A
Hospital Universitario Puerta de Hierro. Majadahonda. Madrid (España)
____
Correspondencia:
Belén Escudero Vilaplana
C/Montesa, 17 – 6ºD
28006 Madrid
Correo electrónico: belenmaria.escudero@salud.madrid.org
____
SUMMARY
Purpose: To assess the adequacy of antiemetic prophylaxis in patients with ovarian cancer treated with carboplatin depending on the dose received (lower or higher than 300 mg/m2).
Material: Retrospective longitudinal study. Analysis period between March 2014 and March 2015. Variables collected: age, body surface area, dose carboplatin, chemotherapy (CT) received, antiemetic prophylaxis, nausea and vomiting (N-V) experienced and dose reductions.
Results: 33 women were included, with a mean age of 58 years and a body surface area of 1.63 m2. Dose of carboplatin received ranged from 343-709 mg. The therapeutic regimens used were 26 carboplatin-paclitaxel, 3 carboplatin-paclitaxel-bevacizumab, 3 carboplatin-gemcitabine-bevacizumab and 2 carboplatin-doxorubicin. All patients received the same antiemetic prophylaxis: dexamethasone 8 mg and ondansetron 8 mg intravenous administration the same day of the cycle (day 1). In addition, they were advised to take ondansetron every 8-12h and metoclopramide before meals for three days after chemotherapy. There were 4 patients who were receiving corticosteroids.
33% (11) patients received doses of carboplatin ≤300 mg/m2. None of them experienced N-V after administration of CT cycle. Of those who had received high doses of the drug (22), 9 (41%) suffered from nausea and 6 (27%) vomiting, which gave partially or totally with taking antiemetics. No dose reduction is required by the occurrence of such events, but 3 of them were prescribed aprepitant in successive cycles CT achieving complete response. Four who had received steroids did not suffer N-V.
Conclusions: The dose of carboplatin received could be decisive when assessing strengthen antiemetic therapy.
Key Words: Carboplatin, prophylaxis, antiemesis, dose.
____
Download PDF: Profilaxis antiemética de carboplatino en cáncer de ovario, ¿moderada o altamente emetógeno?